Synergistic block of SARS-CoV-2 infection by combined drug inhibition of the host entry factors PIKfyve kinase and TMPRSS2 protease.

Kreutzberger, Alex J B; Sanyal, Anwesha; Ojha, Ravi; Pyle, Jesse D; Vapalahti, Olli; Balistreri, Giuseppe; Kirchhausen, Tom.

Affiliation

Kreutzberger AJB; Department of Cell Biology, Harvard Medical School, 200 Longwood Av, Boston, MA 02115, USA.
Sanyal A; Program in Cellular and Molecular Medicine, Boston Children's Hospital, 200 Longwood Av, Boston, MA 02115, USA.
Ojha R; Department of Cell Biology, Harvard Medical School, 200 Longwood Av, Boston, MA 02115, USA.
Pyle JD; Program in Cellular and Molecular Medicine, Boston Children's Hospital, 200 Longwood Av, Boston, MA 02115, USA.
Vapalahti O; Department of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Balistreri G; Program in Virology, Harvard Medical School, 200 Longwood Ave, Boston, MA 02115, USA.
Kirchhausen T; Department of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

bioRxiv ; 2021 Aug 12.

Article in En | MEDLINE | ID: mdl-34100014

Full text: 1 Database: MEDLINE Language: En Journal: BioRxiv Year: 2021 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Language: En Journal: BioRxiv Year: 2021 Type: Article Affiliation country: United States